Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
Crespo-Rodriguez E, Bergerhoff K, Bozhanova G, Foo S, Patin EC, Whittock H, Buus R, Haider S, Muirhead G, Thway K, Newbold K, Coffin RS, Vile RG, Kim D, McLaughlin M, Melcher AA, Harrington KJ, Pedersen M.
Crespo-Rodriguez E, et al. Among authors: thway k.
J Immunother Cancer. 2020 Aug;8(2):e000698. doi: 10.1136/jitc-2020-000698.
J Immunother Cancer. 2020.
PMID: 32759235
Free PMC article.